Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04005053 · ClinicalTrials.gov registry record · Phase 2
Signatures of N-Ac for Non-Suicidal Self-Injury in Adolescents
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT04005053 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 44 participants.
The verdict
NCT04005053, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
To measure NAC-induced changes to concentrations of glutathione (GSH) in the anterior cingulate cortex (ACC) as measured by magnetic resonance spectroscopy (MRS) in 36 adolescents and young adults with NSSI (12 in each group: high, low, and placebo).
Interventions
- DRUG Placebo oral tablet
- DRUG N-acetyl cysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04005053
The ClinicalTrials.gov registry entry for NCT04005053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04005053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04005053 about?
NCT04005053 is a clinical study titled "Signatures of N-Ac for Non-Suicidal Self-Injury in Adolescents". To measure NAC-induced changes to concentrations of glutathione (GSH) in the anterior cingulate cortex (ACC) as measured by magnetic resonance spectroscopy (MRS) in 36 adolescents and young adults with NSSI (12 in each group: high, low, and placebo).
What is the current status of trial NCT04005053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2019-08-01. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT04005053?
The interventions under investigation include: Placebo oral tablet (DRUG), N-acetyl cysteine (DRUG).
Who is sponsoring clinical trial NCT04005053?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.